scholarly journals Clinical efficacy of octreotide acetate combined with thrombin in the treatment of liver cirrhosis complicated with gastrointestinal hemorrhage

Author(s):  
Xiaoyan Wang ◽  
Yanyan Liu ◽  
Jingjing Zhao ◽  
Jinmei Zhang
1970 ◽  
Vol 1 (1) ◽  
Author(s):  
Zhang Xiuqin

Objective: To observe the clinical efficacy of octreotide and thrombin in the treatment of patients with liver cirrhosis, and to explore the mechanism of octreotide and thrombin. Methods: 53 patients with cirrhosis were randomly divided into control group and observation group from January 2014 to January 2016. The control group of 26 patients, given octreotide treatment. Observation group of 27 cases, given octreotide and thrombin combination therapy. Comparison of two groups of patients with clinical efficacy and changes in liver function before and after treatment. Results: The effective rate (88.89%) in the observation group was significantly higher than that in the control group (65.38%), the difference was statistically significant (p < 0.05). Before treatment, the difference of liver function between the two groups was not statistically significant (p > 0.05). After treatment, the liver function indexes of the two groups were improved, and the observation group was superior to the control group, the difference was statistically significant (p < 0.05).


1998 ◽  
Vol 4 (2) ◽  
pp. 80 ◽  
Author(s):  
Zhao-Zhong Li ◽  
Cheng-Dong Wei ◽  
Yao Wang ◽  
Cong Xing ◽  
Hong Guo ◽  
...  

2021 ◽  
Vol 20 (10) ◽  
pp. 2143-2148
Author(s):  
Qiang Chi ◽  
Zhiqiang Lv ◽  
Wenjuan Song

Purpose: To determine the effect of a combination of omeprazole and high-dose proton pump inhibitor (PPI) on the treatment of patients with liver cirrhosis complicated with upper gastrointestinal hemorrhage.Methods: A total of 100 patients with liver cirrhosis and upper gastrointestinal hemorrhage who were admitted to Qingdao Chengyang District People’s Hospital from January 2019 to September 2020 were matched and randomly assigned to a control group and a study group. Patients in both groups received a high-dose PPI treatment, while those in the study group were given omeprazole in addition to highdose PPI. Total treatment effectiveness, incidence of adverse reactions, bleeding volume, hemostasis time, liver function after treatment, Quality of Life Index (QLI) scores, Visual Analogue Scale (VAS) scores, and bleeding (%) at 1, 2 and 4 weeks after treatment were compared for the two groups of patients.Results: Omeprazole-PPI combination produced a much more favorable outcome than treatment with only high-dose PPI, in terms of effectiveness, QLI scores and liver function (p < 0.05). The study group had significantly lower incidence of adverse reactions, bleeding volume, VAS scores, and degree of bleeding at 1, 2 and 4 weeks after treatment, as well as shorter hemostasis time, than the control group (p < 0.05).Conclusion: A combination treatment of omeprazole and high-dose PPI produces better therapeutic effect than high-dose PPI alone, in patients with liver cirrhosis and upper gastrointestinal hemorrhage.


2020 ◽  
Vol 2020 ◽  
pp. 1-15
Author(s):  
Miaomiao Li ◽  
Zeqi Guo ◽  
Dan Zhang ◽  
Xiangbo Xu ◽  
Fernando Gomes Romeiro ◽  
...  

Background and Aim. Liver cirrhosis is often accompanied by insidious cardiac dysfunction. This retrospective cross-sectional study is aimed at exploring the correlation between serum cardiac markers and decompensating events in liver cirrhosis. Methods. Cirrhotic patients who were consecutively hospitalized between January 2016 and March 2019 were screened. Serum cardiac biomarkers at admission, including N-Terminal pro-B-type natriuretic peptide (NT-pro BNP), high-sensitivity cardiac troponin T (hs-cTnT), creatine kinase (CK), creatine kinase MB (CK-MB), and lactate dehydrogenase (LDH), were collected. Acute decompensating events at admission, primarily including ascites, acute gastrointestinal hemorrhage, and acute-on-chronic liver failure (ACLF), were recorded. Results. The NT-pro BNP level was significantly higher in cirrhotic patients with acute decompensating events than in those without any decompensating events (median: 140.75 pg/mL versus 41.86 pg/mL, P<0.001). The NT-pro BNP level significantly correlated with ascites, acute gastrointestinal hemorrhage, and ACLF. The hs-cTnT level was significantly higher in cirrhotic patients with acute decompensating events than in those without decompensating events (median: 0.008 ng/mL versus 0.006 ng/mL, P=0.007). The hs-cTnT level significantly correlated with acute gastrointestinal hemorrhage, but not ascites or ACLF. LDH (185.0 U/L versus 173.5 U/L, P=0.281), CK (71 U/L versus 84 U/L, P=0.157), and CK-MB (29.5 U/L versus 33.0 U/L, P=0.604) levels were not significantly different between cirrhotic patients with and without acute decompensating events. Conclusion. The elevated NT-pro BNP level seems to be closely related to the development of acute decompensating events in liver cirrhosis.


Sign in / Sign up

Export Citation Format

Share Document